Running Point Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Running Point Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-435	Closed	-$51K	–	224
2022 Q2	$51K	Buy	+435	New	+$51.6K	0.03%	156
2021 Q3	–	Sell	-260	Closed	-$43K	–	169
2021 Q2	$43K	Hold	260	–	–	0.02%	119
2021 Q1	$39K	Buy	+260	New	+$41.3K	0.02%	105

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Running Point Capital Advisors's IBB Position: Q3 2022 in Review

Running Point Capital Advisors sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 435 shares — an estimated $51K sold.

Running Point Capital Advisors first reported a position in IBB in Q1 2021 and held it in 3 quarters. The position peaked at $51K in Q2 2022. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

Running Point Capital Advisors reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
Running Point Capital Advisors sold 435 iShares Biotechnology ETF shares in Q3 2022, an estimated $51K.
Running Point Capital Advisors first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 3 quarters.
Running Point Capital Advisors's iShares Biotechnology ETF position peaked at $51K in Q2 2022.
829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Running Point Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.